drugset
drugset / Trial / NCT06144424

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

NCT06144424 ↗

Phase 2 Completed 32 enrolled Escient Pharmaceuticals, Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

This Phase 2a trial will evaluate the effects of EP262 in subjects with atopic dermatitis

Timeline

Start
2023-10-25
Primary completion
2024-07-31
Completion
2024-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject EP262 Unknown 150 mg Oral

Indications

atopic eczema